anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Tracheal collapse (TC), a common disease in dogs, is characterized by cough; however, little is known about the serum biomarkers that can objectively evaluate the severity of cough in canine TC. Furthermore, studies elucidating the relationship of fluoroscopic characteristics with the severity of cough are lacking. Therefore, this study aimed to evaluate the relationship between cough severity and clinical characteristics, fluoroscopic images, and new serum biomarkers in canine TC.
RESULTS: Fifty-one client-owned dogs diagnosed with TC based on fluoroscopic and clinical signs were enrolled in this study and divided into three groups according to the severity of cough (grade of cough: 0, 1, and 2). Signalments, comorbidities, and fluoroscopic characteristics were compared among the groups retrospectively. The serum matrix metalloproteinase-9 (MMP-9), interleukin-6 (IL-6), surfactant protein-A (SP-A), and syndecan-1 (SDC-1) levels were measured in all groups. No significant differences in age, breed, sex, or clinical history were observed among the groups. Concomitant pharyngeal collapse increased significantly with the severity of cough (p = .031). Based on the fluoroscopic characteristics, the TC grade of the carinal region increased significantly and consistently with the grade of cough (p = .03). The serum MMP-9 level was significantly higher in the grade 2 group than that in the grade 0 group (p = .014). The serum IL-6 level was significantly lower in the grade 1 group than that in the grade 0 group (p = .020). The serum SP-A and SDC-1 levels did not differ significantly among the groups.
CONCLUSIONS: The severity of cough with the progression of TC can be predicted with the fluoroscopic TC grade at the carinal region. MMP-9 may be used as an objective serum biomarker that represents cough severity to understand the pathogenesis.
The present invention provides a preparation method for an oil agent for reducing a gastrointestinal reaction caused by sulforaphane and sulforaphane. The oil agent comprises sulforaphane and sulforaphene as effective components. The weight percentage of sulforaphane and sulforaphene is 0.1-50%. Auxiliary material vegetable oil used for preparing the oil agent is one or a mixture of more of soybean oil, corn oil, peanut oil, sesame oil, cottonseed oil, linseed oil, castor oil, rapeseed oil, sunflower seed oil, camellia oleosa seed oil, and olive oil. Sulforaphane and sulforaphene are mixed with an auxiliary material to prepare a capsule. The oil agent can be used for reducing the gastrointestinal reaction caused by sulforaphane and sulforaphane.
The present invention relates to three-dimensional volumes of interest in ultrasound imaging. An ultrasound imaging (38) of the volume of interest is performed. An object of interest is automatically positioned (32) from the volume scan. In one approach, a geometric bounding box surrounding the object is found by a classifier. In another method, an option for zooming to the subject is indicated (33) to the patient. The scan area is automatically defined (34) around the object or bounding box, whether or not in response to a user selection of an option. The scan region is shaped based on an ultrasound scan format, but is smaller than the volume. The volume of interest defined by the scan region is used to generate (38) an image having a greater temporal and/or spatial resolution than a scan (30) of the entire original volume.
For patients enrolled in the control group, the participants will undergo calibration of the Delfi Personalized Tourniquet System to measure limb occlusion pressure and will wear the cuff during completion of the exercises with minimal inflation (approximately 5%), to hold the cuff in place during treatment. This will act as a sham.
Infants will be enrolled and randomized at 30 0/7 weeks postmenstrual age. The Earlier Oral Feeding group will initiate oral feedings at 30 0/7 weeks postmenstrual age. The Later Oral Feeding group will initiate oral feedings at 33 0/7 weeks postmenstrual age. The number of oral feeding attempts will be advanced according to a feeding progression protocol for both groups. Successful completion of a feeding is defined as oral completion of the full volume of a feeding within 30 minutes, without a bradycardic episode (heart rate \<100 beats per minute) or desaturation (oxygen saturation decrease \>5% from baseline values). If infant does not successfully complete \>95% of the total prescribed volume of a feeding, the remainder of the volume will be supplied via gastric tube. All oral feedings will be performed by bedside nurses, or by a parent with observation by the nursing staff, with continuous cardiorespiratory and pulse oximetry monitoring. Individual oral feeding attempts for both groups will continue until one of the following occurs despite appropriate pacing of the feeding: 1) the feeding is completed 2) feeding duration of 30 minutes 3) adverse event during a feeding \[multiple bradycardic episodes (3 episodes of heart rate \<100 beats per minute), bradycardia with choking episode, single severe bradycardia (heart rate \<60)\]. If the infant experiences an adverse event during an oral feeding attempt, oral feeding attempts will be held for 2 days.
Patients will receive 6-8 treatments additional loco-regional hyperthermia concurrent to re-irradiation. Hyperthermia will start on the third day of fractionated radiotherapy and will be given twice per week. According to site of recurrent disease either deep-regional, capacitive or superficial hyperthermia devices may be used.
PROBLEM TO BE SOLVED: To obtain a warm sense-giving composition having excellent sustainability of warm sense and having enhanced percutaneous absorption of an antiinflammatory agent when included in a non-steroidal antiinflammatory agent-containing preparation for external use for skin because a warm sense- giving substance is clathrated in a cyclodextrin, by including the warm sense- giving substance and a cyclodextrin. SOLUTION: This composition is obtained by including (A) a warm sense- giving substance and (B) a cyclodextrin (e.g. α-cyclodextrin). It is preferable to use a combination of at least two substances from red pepper (e.g. capsaicin and extracts from red pepper) as component A. Preferably the weight ratio of these substances is 1-5,000. Preferably the component A/component B weight ratio is 0.1-10. It is preferable to include the composition in a non-steroidal antiinflammatory agent-containing preparation for external use for skin at 0.01-1 wt.%. A small amount of a refreshing sense-giving agent can be added to component A to effectively enhance the warm sense.
Osteosarcoma is a highly metastatic, aggressive bone cancer that occurs in children and young adults worldwide. Circular RNAs (circRNAs) are crucial molecules for osteosarcoma progression. In this study, we aimed to investigate the impact of circMRPS35 overexpression and its interaction with FOXO1 via evaluating apoptosis, cell cycle, and bioinformatic analyses on the malignant development of osteosarcoma in MG63 and MNNG/HOS cells. We found that circMRPS35 overexpression reduced osteosarcoma cell viability and inhibited tumor growth in vivo. It increased the apoptosis rate and induced cell cycle arrest in osteosarcoma cells. We identified a potential interaction between circMRPS35 and FOXO1 with miR-105-5p using bioinformatics analysis. Overexpression of circMRPS35 decreased miR-105-5p expression, whereas miR-105-5p mimic treatment increased its expression. This mimic also suppressed the luciferase activity of circMRPS35 and FOXO1 and reduced FOXO1 expression. Overexpression of circMRPS35 elevated FOXO1 protein levels, but this effect was reversed by co-treatment with the miR-105-5p mimic. We demonstrated that inhibiting miR-105-5p decreased viability and induced apoptosis. Overexpression of FOXO1 or treatment with a miR-105-5p inhibitor could counteract the effects of circMRPS35 on viability and apoptosis in osteosarcoma cells. Therefore, we concluded that circMRPS35 suppressed the malignant progression of osteosarcoma via targeting the miR-105-5p/FOXO1 axis.
BRONCHITOL (mannitol) inhalation powder contains D-Mannitol (referred to throughout as mannitol) as the active ingredient. Mannitol is a hexahydric sugar alcohol, with the following chemical name hexane-1,2,3,4,5,6-hexol and chemical structure:

Mannitol is a white or almost white crystalline powder or free-flowing granules with an empirical formula of C6H14O6 and molecular weight of 182.2. Mannitol is freely soluble in water, and very slightly soluble in alcohol. Mannitol shows polymorphism.

BRONCHITOL contains mannitol powder spray dried into particles of respirable size filled into clear, colorless hard gelatin capsules. There are no inactive ingredients in BRONCHITOL.

The accompanying white plastic inhaler is comprised of a mouthpiece, blue piercing buttons, capsule chamber, and a removable cap. A blister pack consists of 10 capsules, each containing 40 mg mannitol. After a capsule is placed in the

capsule chamber and pierced by firmly pressing and releasing the buttons on the side of the device, the powder within the capsule becomes exposed and ready for dispersion into the airstream generated by the patient upon inhalation through the mouthpiece. Under standardized in vitro test conditions, the inhaler delivers 32.2 mg of mannitol per inhalation when tested at a flow rate of 60 L/min for 2 seconds. The actual amount of drug delivered to the lungs will depend on patient factors, such as inspiratory flow profile.
The purpose of this study is to determine whether 12 weeks of once-weekly treatment with the glucagon-like peptide-1 receptor (GLP-1R) agonist, semaglutide, will reduce illicit opioid use over a 19 week period (133 days) among individuals in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment (i.e., medication for opioid use disorder). Following successful consent and screening, participants will complete a baseline evaluation and be randomly assigned to semaglutide or placebo control arms, in a 1:1 ratio using a permuted-block randomization algorithm stratified by site and), and begin a 1-week baseline period. Semaglutide (injector pen) or placebo will be administered as a subcutaneously (SC) once per week for 12 weeks, starting at a dose of 0.25 mg SC and advanced on a fixed-flexible dose schedule, based on tolerability, to a target dose of 1.0 mg SC per week, or the maximum tolerated dose if less than 1.0 mg. Participants will receive study intervention in an outpatient setting for a total of 12 weeks. After 4 weeks at the target (1.0 mg) or maximum the highest dose tolerated dose, participants will discontinue semaglutide or placebo and be observed for an additional week (wash-out period). A final follow-up visit will then take place 5 weeks after the last treatment visit.

During each study visit, participants will undergo urine drug screening and pregnancy testing, vital signs collection, and complete mental health and drug use questionnaires. Participants will also complete smartphone surveys sent at set times during the study. Blood samples will be collected at 2 of the visits (screening and the study week 14) and a physical examination and medical history collection will be done at the baseline visit
Because serious GI tract ulcerations and bleeding can occur without warning symptoms, physicians should monitor for signs or symptoms of GI bleeding. Patients on long-term treatment with NSAIDs should have their CBC and a chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or renal disease develop, systemic manifestations occur (eg, eosinophilia, rash, etc.) or if abnormal liver tests persist or worsen, VIMOVO should be discontinued. 

Patients with initial hemoglobin values of 10 g or less who are to receive long-term therapy should have hemoglobin values determined periodically.

Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Providers should temporarily stop esomeprazole treatment before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g. for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary [see Pharmacodynamics (12.2)].
This group will getting treadmill training will be started along with conventional therapy group. Training protocol will be standardized and follow FITT protocol for 12 weeks.
Meal ingestion releases gut hormones which stimulate insulin secretion. A most important gut hormone is the incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 is rapidly degraded and inactivated after its release by the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 therefore increases the concentration of active GLP-1 after meal ingestion, which augments insulin secretion. How this process is regulated after ingested of different individual macronutrients is not known. Therefore, this study examines the influence of ingestion of fat, protein, glucose or mixed meal on the concentrations of incretin hormones and insulin secretion with or without concomitant administration of a DPP-4 inhibitor (sitagliptin).
METHOD AND SYSTEM FOR IDENTIFICATION OF CEREBROVASCULAR ABNORMALITIES System and methods are disclosed for identifying as well as distinguishing between cerebrovascular abnormalities. The system comprises a medical imaging device configured for capturing plurality of images of a cerebrovascular region of a subject and communicating the same to a computing device. The computing device comprises one or more modules configured for extracting features from the captured images, grouping the cerebrovascular region into one of blood vessel type and non-blood vessel type and further extracting features associated with the blood vessels to classify each point on the blood vessel into one of a non-branching, converging and diverging type. The system further comprises a user interface for interactively viewing the results of the classification thereby providing a means to identify cerebrovascular abnormalities. To be published with FIG. 1 Training Data Receiving Module Graphical Processing Module 1 14 Extractor Module Classifier Module A' User Interface Processor(s) 122 Module 120
Extracorporeal membrane oxygenation (ECMO) can be a lifesaving procedure for the sickest patients in the Intensive Care Unit (ICU) who are at risk of death from severe cardiac and respiratory failure. ECMO is a device which pumps blood out of the body and returns it back after adding oxygen and removing carbon dioxide. While potentially life-saving, ECMO is associated with high use of critical care resources and increased risk of adverse outcomes in survivors.

The BLENDER Trial is a multicentre trial in ECMO patients to determine whether a conservative oxygen strategy during ECMO reduces ICU length of stay and improves patient outcomes compared to a liberal oxygen strategy. Both strategies are currently standard practice worldwide, however, there is no consensus to which strategy is better for our patients. This trial aims to utilise an existing intensive care registry and will recruit 300 patients with life threatening acute cardiac or respiratory failure. If the BLENDER Trial confirms that one oxygen management strategy is more effective than the other, its findings may improve the lives of critically ill Australians and inform clinical practice worldwide.
Subjects will be provided with daily 5 mg of nebivolol for the first 2 weeks. Subjects receive additional daily doses of 10 mg nebivolol for the remainder of the study period. The dose remains at 5 mg per day, however, if BP falls below 110/70 during the first 2 weeks. Subjects will continue taking the drug during the 2-week follow-up period.
BACKGROUND/PURPOSE: Facial asymmetry is common in Class III patients requiring orthognathic surgery. This study aimed to analyze jaw bone position after surgical-orthodontic treatment in three types of skeletal Class III asymmetry patients.
METHODS: The retrospective study included 30 Class III patients who underwent surgical-orthodontic treatment comprising LeFort I osteotomy and bilateral sagittal split osteotomy (BSSO) without genioplasty. Cone-beam computed tomography (CBCT) images obtained before surgery (T1) and after post-surgical orthodontic treatment (T2) were superimposed with voxel-based registration. Patients were classified into three groups based on T1 CBCT scans. Groups 1 and 2 exhibited menton and ramus deviated to the same side. Menton deviation was larger than ramus width asymmetry in group 1, while the reverse was true for group 2. Group 3 had menton deviation contralateral to the side with greater ramus width.
RESULTS: Menton deviation after treatment was improved in all groups. Ramus width asymmetry and coronal ramus angle difference decreased in groups 1 and 2. Neither improvement nor deterioration of ramus width asymmetry was noted for group 3. Comparing to groups 1 and 2, group 3 had greater roll and yaw rotations of distal segment, more upward pitch of proximal segment on chin deviation side, and largest inward yaw as well as backward translation of proximal segment on non-deviation side.
CONCLUSION: The positional changes of osteotomy segments differed among three types of mandibular asymmetry. Special attention should be given to the atypical mandibular asymmetry with mandibular body and ramus deviating to opposite directions during surgical correction of jaw deflection.
The study group was treated with Rugdenzengsheng No. 1 prescription for 2 courses.
A detergent composition contains an N-hydroxyalkyl-N-methyltaurine-N-oxide of the formula <FORM:1009190/C4-C5/1> wherein R represents a C8- 18 alkyl group and M is hydrogen or an alkali metal, particularly sodiums together with conventional builders such as tetrapotassium pyrophosphate and alkali metal suphates, carbonates, silicates and borates; a carboxymethyl cellulose soil suspending agent and other synthetic detergents, soaps, perfumes, abrasives, foam stabilizers, germicidal agents and colouring agents.  The composition may be in the form of dish-washing detergents, non-soap bars, soap bars, bars containing mixtures of soaps and non-soaps, and shampoos. Specification 1,009,189 is referred to.ALSO:The invention comprises compounds of the formula <FORM:1009190/C2/1> wherein R represents a C8- 18 alkyl group and M is hydrogen or an alkali metal.  The above N-hydroxyalkyl - N - methyltaurine - N - oxides are prepared by oxidation of the corresponding N - hydroxyalkyl - N - methyltaurines, e.g. with hydrogen peroxide or ozone.  The compounds are used as ingredients of detergent compositions and dentifrice compositions. Specification 1,009,189 is referred to.ALSO:A dentifrice composition contains as an essential ingredient an N-hydroxyalkyl-N-methyltaurine-N-oxide detergent of the formula <FORM:1009190/A5-A6/1> wherein R represents a C8-18 alkyl group and M is hydrogen or an alkali metal, together with an abrasive such as dicalcium phosphate dihydrate and other conventional ingredients such as glycerine.  Specification 1,009,189 is referred to.
Unblinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Based on the retrospective registry in Zhejiang Provincial Immunization Information System, healthy children aged 6 years from 5 cohorts were included according to their previous immunization schedules on JE: 3 doses of JEV-I (Group 1), JEV-L+ JEV-I (Group 2), JEV-L+ JEV-I + JEV-I (Group 3), JEV-I + JEV-I+ JEV-L (Group 4), and 2 doses of JEV-L (Group 5). According to immunization programs in China, a booster dose of JEV-I is needed at the age of 6 for Group 1 and Group 2. A pre-vaccination blood sample (2.5ml) will be collected to evaluate the proportions of seropositivity before the booster dose of JEV-I. A second blood sample will be collected 28-35 days after the booster dose. Immunogenicity of the booster dose will be assessed by seroconversion rates, proportions of seropositivity and GMTs for these two groups. In addition, safety will be assessed with the occurrence of adverse events reported in these two groups. For the rest three groups who have completed the immunization schedules on JE, only one blood sample will be taken at the age of 6 to evaluate the proportions of seropositivity and GMTs after 4 years post the complete immunization schedules. Plague reduction neutralization test (PRNT) against both vaccine strains (SA-14-14-2 strain for JEV-L and Beijing P3 strain for JEV-I) will be used to test neutralizing antibody titers, so as to avoid potential bias in favor of either vaccine. PRNT50 titers (the reciprocal of the serum dilution that reduced the virus plaque count by 50% compared with the virus-only controls) ≥ 1:10 are deemed as positive.
Participant program manual, diet and activity logs, hour long remote sessions with a Health Promotionist. Will have physical measures taken at baseline, 3 months, 6 months, 9 months, and 12 months.
A composition for administration to a subject is disclosed. The composition comprises at least one plant active ingredient. The plant active ingredient is present in the composition in an amount effective to inhibit Xanthine Oxidase (XO) in the subject. The plant active component comprises at least one extract selected from the group consisting of: i) An extract of lonicera japonica; ii) an extract of lysimachia foenum-graecum; and iii) a combination of i) and ii). The composition may further comprise one or more supplemental extracts. The composition may be in the form of an oral composition, for example for ingestion. The composition may also be in the form of a topical composition, e.g. for topical administration. Also provided is a method of inhibiting Xanthine Oxidase (XO) in a subject. The method comprises administering to a subject an effective amount of the composition.
FIELD: medicine, phytotherapy, pharmacy. SUBSTANCE: invention relates to the development of pharmacological agents of vegetable origin eliciting sedative, spasmolytic, anti-inflammatory, cholagogic, general tonic and expectorative effect. Invention proposes an agent comprising pot-marigold flowers, nettle leaves, wild rose fruits, thyme herb, common balm herb, marjoram herb, ethyl alcohol, sugar, color and water taken in the definite ratio of components. Agent shows broad spectrum of pharmacological effect being without adverse symptoms. EFFECT: valuable medicinal properties of agent. 2 cl, 6 tbl
The invention provides application of a protein DEPDC1 as a marker for diagnosing triple negative breast cancer. The invention also provides application of the miR-26b in preparation of a medicine for treating triple negative breast cancer. The invention also provides application of the miR-26b in preparation of a drug for inhibiting DEPDC1mRNA expression. The invention finds that DEPDC1 expression is obviously higher than that of matched paracarcinoma tissues in triple-negative breast cancer tissues. Overexpression of DEPDC1 in triple negative breast cancer cells can promote cell growth and tumor formation by up-regulating FOXM1 expression. In contrast, knockdown of DEPDC1 showed the opposite effect. Moreover, in triple negative breast cancer, miR-26b as a tumor suppressor can directly inhibit DEPDC1 expression and weaken the promoting effect of DEPDC1 on cell growth and clonogenic formation. The invention provides a new important mechanism for the generation, development and regulation of triple negative breast cancer.